Skin and Joints Podcast cover art

Skin and Joints Podcast

Skin and Joints Podcast

By: Mimi Tran Aaron Sihota Danny Mansour Ashley Yip Julia Tan Touraj Khosravi Anastasiya Muntyanu
Listen for free

Summary

 A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.2026 Skin and Joints Podcast Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive

    AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive
    Apr 7 2026
    🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data. In Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies. Because patients do not walk into clinic asking if their EASI score improved by 70%. They ask: “Will I sleep?”“Will the itch stop?”“Can I focus at work or school?”“Can I stop thinking about my eczema every single day?” Our conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis. We also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders? Think of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care. Learning Objectives: By the end of this episode, listeners will be able to: Describe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis.Discuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone.Interpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies.Identify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice.Apply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care. Skin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting. Part 2 is already warming up in the bullpen. REFERENCES: Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻...
    Show More Show Less
    26 mins
  • World Psoriasis Day: From Stigma to Skin Clearance with Dr. Jessica Asgarpour

    World Psoriasis Day: From Stigma to Skin Clearance with Dr. Jessica Asgarpour
    Oct 28 2025

    🎙️ World Psoriasis Day Special

    This special World Psoriasis Day episode of The Skin and Joints Podcast shines a light on the evolving psoriasis journey—from the first plaque to total skin clearance. Dermatologist Dr. Jessica Asgarpour, now back in her sunny hometown of Calgary, joins us for an honest, hopeful conversation about how far psoriasis care has come—and where it’s headed next.

    From coal tar and cumbersome creams to once-every-12-week biologic injections, Dr. Asgarpour unpacks the “treatment ladder” and what really determines when to climb it. Together they explore:

    Why World Psoriasis Day (Oct 29) matters for awareness, stigma reduction, and timely re-referral

    How to recognize when a patient is undertreated and ready for escalation

    The topical-to-systemic continuum—including steroid-free innovations, orals vs. biologics, and the occasional role for IV therapy

    Real-world barriers in access and adherence—from referral deserts to needle phobia

    Matching therapy to patient lifestyle, comorbidities, and comfort level (“the clinic playbook”)

    Why dermatologists today can say, confidently, that there is hope for every patient

    It’s part myth-busting, part motivation—a must-listen whether you’re a clinician optimizing care or a patient ready to revisit your treatment options.

    🎯 Learning Objectives

    After listening to this episode, participants will be able to:

    • Describe the modern therapeutic ladder for psoriasis, from topicals and orals to biologics and infusions.
    • Identify clinical and quality-of-life criteria that signal the need for treatment escalation.
    • Discuss common barriers leading to undertreatment and strategies to enhance patient access and adherence.
    • Compare classes of biologic agents (TNF-α, IL-17, IL-23, IL-12/23) and their practical considerations in real-world care.
    • Empower patients with evidence-based reassurance about safety, efficacy, and long-term outcomes of advanced therapies.

    🩵 World Psoriasis Day is more than awareness—it’s a call to action for clear skin, renewed confidence, and collaborative care.
    #WorldPsoriasisDay #SkinAndJointsPodcast #PsoriasisAwareness #Dermatology #Biologics #PatientJourney #ClearSkinAhead

    Supported by SUN Pharma.

    ABOUT Dr. Jessica Asgarpour Dermatologist, Calgary, AB

    Board-certified in both Canada and the U.S., Dr. Asgarpour completed medical school at the Cumming School of Medicine and her Dermatology residency at the University of Alberta. She practices medical, surgical, and cosmetic dermatology with a special interest in hidradenitis suppurativa and deroofing surgeries, as well as acne, psoriasis, eczema, skin cancer, and women’s health. She is currently working at the Skin Health and Wellness Centre in Calgary. She is a lecturer at the University of Toronto, a courtesy clinical associate at Women’s College Hospital, and is an active investigator for ongoing clinical trials in inflammatory diseases. She is a board member on the Canadian Hidradenitis Suppurativa foundation.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    30 mins
  • (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    Oct 8 2025
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    Show More Show Less
    23 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet